

ATTORNEY'S DOCKET NO. R0547/7007 (Formerly B0801/7137)

(ERG/KA)

. 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

James K. Liao, et al.

Serial No.

09/273,445 March 19, 1999

Filed: For:

UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE

SYNTHASE BY HMG-COA REDUCTASE INHIBITORS

Examiner:

Webman E. J.

Art Unit:

1617

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 16th day of March, 2001.

Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Sir:

Transmitted herewith are the following documents:

Preliminary Amendment [X]

Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

No fee is required. If any fee is determined to be due by the Examiner, the Examiner is authorized to charged the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,

Attorney's Docket No.: R0547/7007

Date: March 16, 2001

XNDD

Edward R. Gates, Reg. No.: 31,616

WOLF, GREENFIELD & SACKS

600 Atlantic Avenue

Boston, MA 02210-2211



3/29

ATTORNEY'S DOCKET NO. R0547/7007 (Formerly B0801/7137) (ERG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

James K. Liao, et al.

Serial No.

09/273,445

Filed:

March 19, 1999

For:

UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE

SYNTHASE BY HMG-COA REDUCTASE INHIBITORS

Examiner:

Webman E. J.

Art Unit:

1617

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 16th day of March, 2001.

Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the claims:

Please add the following new claims:

01	224 (New).	The method of claim 46, further comprising co-administering an estrogen or an ACE inhibitor.
	225(New).	The method of claim 46, further comprising co-administering an estrogen or an ACE inhibitor.
	226 (New).	The method of claim 91, further comprising co-administering an estrogen or an ACE inhibitor.
	227 (New).	The method of claim 113, further comprising co-administering an estroger or an ACE inhibitor.
	228 (New).	The method of claim 131, further comprising co-administering an estaden chan ATD inhibitor.